NewsERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement
License allows Lepton, with their proprietary Castling Technology, to develop and commercialize products and services using CRISPR/Cas9 technology Dublin, Ireland and Zichron Yakov, Israel, 26 July 2022: ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Lepton Pharmaceuticals LTD (‘Lepton”). This is a non-exclusive licensing agreement granting Lepton access to the...